By Connor Hart
AC Immune amended its collaboration agreement with Eli Lilly, extending development of potential treatments for Alzheimer's disease and other neurodegenerative diseases.
The Swiss biopharmaceutical company said Tuesday that the revised agreement expands the partnership, which seeks to develop Tau aggregation-inhibitor small molecules.
Under the terms , AC Immune will receive an upfront payment of 10 million Swiss francs, equivalent to about $12.5 million, as well as additional payment tied to the initiation of Phase 1 clinical trials.
The company said it also remains eligible for more than 1.7 billion Swiss francs in development, regulatory and commercial milestones, in addition to tiered royalties in the low double digits.
The collaboration builds on a 2018 licensing deal between the companies and focuses on Tau-targeting small molecules designed to inhibit aggregation of the Tau protein, a key driver of neurodegeneration in Alzheimer's disease.
AC Immune shares rose 4.4%, to $2.82, in premarket trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 07, 2026 07:40 ET (11:40 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.